Status | Study |
RECRUITING |
Study Name: Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis Condition: Date: 2023-06-05 Interventions: Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery fro |
NOT_YET_RECRUITING |
Study Name: Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma Condition: Date: 2023-05-30 Interventions: PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch.The permeation is brushed onto the resected tumor |
Not yet recruiting |
Study Name: Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma Condition: Hepatitis C Date: 2017-04-03 Interventions: Other: oral squamous cell carcinoma Histological diagnosis of H&E stained sections will be performed |
Recruiting |
Study Name: A Dye for the Detection of Cancer of the Tongue and Mouth Condition: Oral Squamous Cell Carcinoma (OSCC) Date: 2017-03-15 Interventions: Drug: Olaparib For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then s |
Completed |
Study Name: Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity Condition: Oral Lichen Planus Oral Squamous Cell Carcinoma Date: 2017-01-18 Interventions: Genetic: global proteomic profiling Global proteomic profiling was performed on OLP and OSCC samples and |
Active, not recruiting |
Study Name: One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma Condition: cN0 Oral Squamous Cell Carcinomas Date: 2016-07-19 |
Recruiting |
Study Name: Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study Condition: Oral Squamous Cell Carcinoma Carcinoma of Buccal Mucosa Date: 2016-04-20 Interventions: Drug: Arm1 Drug (Celecoxib as |
Recruiting |
Study Name: Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Condition: Oral Squamous Cell Carcinoma Date: 2016-03-22 Interventions: Drug: Celecoxib 200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months |
Completed |
Study Name: Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions Condition: Precancerous Conditions Oral Cancer Date: 2014-12-18 |
Active, not recruiting |
Study Name: Fluorescent Visualization in Early Oral Cancer Condition: Oral Squamous Cell Carcinoma or Severe Dysplasia Date: 2014-12-01 Interventions: Procedure: resection of oral cancer |